Last mentioned: Mar 8, 2026
Q4 2025 Earnings
Both companies report full-year 2025 results and 2026 guidance.
Olpruva Scaling
Zevra reports steady growth in urea cycle disorder market share.
Novartis Expansion
Voyager expands its capsid discovery collaboration with Novartis.
Miplyffa Approval
Zevra receives FDA approval for arimoclomol in NPC treatment.
Voyager Technologies and Zevra Therapeutics are preparing to report Q4 2025 results, highlighting a pivotal period for gene therapy platforms and rare disease commercialization. Investors are focused on Voyager's partnership revenue and Zevra's initial market traction for its newly approved NPC treatment.
Zevra Therapeutics has appointed Justin Renz as its new Chief Financial Officer, bringing over 20 years of biotech leadership to the rare disease specialist. The move comes as Zevra prioritizes the commercial rollout of Miplyffa, its recently FDA-approved treatment for Niemann-Pick disease type C.